0001104659-21-141746.txt : 20211119 0001104659-21-141746.hdr.sgml : 20211119 20211119132805 ACCESSION NUMBER: 0001104659-21-141746 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211117 FILED AS OF DATE: 20211119 DATE AS OF CHANGE: 20211119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kamarck Michael E. CENTRAL INDEX KEY: 0001450730 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36596 FILM NUMBER: 211427682 MAIL ADDRESS: STREET 1: C/O UNILIFE CORPORATION STREET 2: 250 CROSS FARM LANE CITY: YORK STATE: PA ZIP: 17406 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Trillium Therapeutics Inc. CENTRAL INDEX KEY: 0001616212 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2488 DUNWIN DRIVE CITY: MISSISSAUGA STATE: A6 ZIP: L5L 1J9 BUSINESS PHONE: (416) 595-0627 MAIL ADDRESS: STREET 1: 2488 DUNWIN DRIVE CITY: MISSISSAUGA STATE: A6 ZIP: L5L 1J9 4 1 tm2133436-6_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-11-17 1 0001616212 Trillium Therapeutics Inc. TRIL 0001450730 Kamarck Michael E. C/O TRILLIUM THERAPEUTICS INC. 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9 ONTARIO, CANADA 1 0 0 0 Stock Option (Right to Buy) 14.77 2021-11-17 4 D 0 67000 0 D 2030-09-17 Common Shares 67000 0 D On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. /s/ James Parsons, Attorney-in-Fact 2021-11-19